

MASTER « *In Silico* Drug Design » 1^{ère} année

PROPOSITION DE STAGE Année Universitaire 2020 / 21



A envoyer à Mr Pr Taboureau
olivier.taboureau@univ-paris-diderot.fr

Nom du Responsable du Laboratoire :

Affiliation administrative (CNRS, INSERM ...) : BFA, CNRS UMR 8251, INSERM U1133 CMPLI, Université Paris Diderot.

Adresse précise du Laboratoire : Université Paris Diderot, Bâtiment Lamarck A, 35 rue Hélène Brion, 75205 Paris Cedex

Nom du Responsable de l'équipe d'accueil : Pierre Tufféry

E-mail : pierre.tuffery@u-paris.fr

Nom du Responsable du stage : Leslie Regad

Numéro de Téléphone : 01 57 27 82 72

E-mail : leslie.regad@u-paris.fr

Titre du stage : Characterization of the structural asymmetry in the HIV-2 protease

Description du sujet (quelques lignes) : HIV-2 is a retrovirus discovered a few years after HIV-1. HIV-2 infections are restricted mainly to West Africa. HIV-1 and HIV-2 are currently treated with the same therapeutic arsenal, which consists of drugs targeting integrase, reverse transcriptase, fusion protein and protease (PR). However, HIV-2 is naturally resistant to all non-nucleoside inhibitors of reverse transcriptase or fusion inhibitors. HIV-2 has also demonstrated reduced susceptibility to protease inhibitors (PIs) [1–4].

PR is an effective therapeutic target for treating HIV infection because of its essential role in hydrolysing the viral precursor polyprotein during infectious viral particle maturation. PR is an homodimer of 99 amino acid per monomers. Ligand (Substrats and IPs) bound the PR in a pocket located at the monomer interface. Ligand binding induces structural deformation allowing the closing of ligand-binding pocket. In the aim to study the natural resistance of PR2 against IPs, we have previously developed in silico protocols to characterize PR2 structure and flexibility [5], its structural asymmetry [6-7], to compare PR1 and PR2 complexes [8] and their PI-binding pockets [9]. During these analysis, we have shown that although PR2 is an homodimer its two monomers exhibit different global and local conformations [6-7, 9-10]. This structural asymmetry is induced by ligand binding [6], crystal packing [7, 9], intrinsic flexibility of PR2 [6-7]. This asymmetry is important for the recognition, specificity and ligand binding [6].

In this study, we will explore the link between the structural asymmetry of PR2 and its intrinsic flexibility. To do so, we will study and compare the PR2 structural asymmetry during molecular dynamics simulations ran under different conditions (protonation, implicit or explicit solvent, ...). More precisely, we will locate structural asymmetry residues in the different structures extracted from the generated trajectories and will analyze their position according to the flexible regions. We will also study the impact of protonation and water-molecule interactions on the PR2 asymmetry. For these analyses, student will use python and R programming languages and PyMoL software.

1. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. *Chem. Biol. Drug Des.* 71:298–305, 2008.
2. Raugi DN, Smith RA, Gottlieb GS. & for the University of Washington-Dakar HIV-2 Study Group. Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors. *J. Virol.* 90:1062–1069, 2016.

3. Bénard A, et al. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. *AIDS*. 23:1171–1179, 2009.
 4. Ren J, et al. Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. *PNAS U. S. A.* 99:14410–1441, 2002.
 5. Triki et al., Characterizing the structural variability of HIV-2 protease upon the binding of diverse ligands using a structural alphabet approach. *JBSD*. 28:1-13, 2018.
 6. Triki et al. Analysis of the HIV-2 protease's adaptation to various ligands: characterization of backbone asymmetry using a structural alphabet. *Sci Rep*. 8:710n 2018.
 7. Ollitrault et al., Characterization of HIV-2 protease structure by studying its asymmetry at different levels of protein description. *Symmetry*. 10:644, 2018.
 8. Triki et al., Exploration of the effect of sequence variations located inside the binding pocket of HIV-1 and HIV-2 proteases. *Sci Rep*. 8: 5789, 2018.
 9. Triki et al., Exploration of effects of sequence variations between HIV-1 and HIV-2 proteases on their three-dimensional structures. *JBSD*. 38:5014-26, 2020
 10. Laville et al., Impacts of drug-resistance mutations on the structural asymmetry of the HIV-2 protease. *BMC Mol Cell Biol*. 51:46, 2020.
-